$0.03
55.07% yesterday
Nasdaq, Feb 27, 03:30 pm CET
ISIN
US68217N1054
Symbol
OMGA
Sector
Industry

Omega Therapeutics Inc Stock price

$0.03
-0.41 93.01% 1M
-1.44 97.89% 6M
-0.71 95.84% YTD
-4.19 99.27% 1Y
-11.84 99.74% 3Y
-15.97 99.81% 5Y
-15.97 99.81% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.04 55.07%
ISIN
US68217N1054
Symbol
OMGA
Sector
Industry

Key metrics

Market capitalization $1.72m
Enterprise Value $99.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 12.24
P/S ratio (TTM) P/S ratio 0.21
P/B ratio (TTM) P/B ratio 0.15
Revenue growth (TTM) Revenue growth 184.93%
Revenue (TTM) Revenue $8.10m
EBIT (operating result TTM) EBIT $-74.15m
Free Cash Flow (TTM) Free Cash Flow $-57.64m
Cash position $30.72m
EPS (TTM) EPS $-1.33
P/E forward negative
P/S forward 1.77
EV/Sales forward 15.30
Short interest 26.91%
Show more

Is Omega Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Omega Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Omega Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Omega Therapeutics Inc:

Buy
100%

Financial data from Omega Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
8.10 8.10
185% 185%
100%
- Direct Costs 7.31 7.31
16% 16%
90%
0.79 0.79
123% 123%
10%
- Selling and Administrative Expenses 11 11
20% 20%
135%
- Research and Development Expense 57 57
35% 35%
700%
-67 -67
36% 36%
-825%
- Depreciation and Amortization 7.31 7.31
16% 16%
90%
EBIT (Operating Income) EBIT -74 -74
33% 33%
-915%
Net Profit -73 -73
32% 32%
-902%

In millions USD.

Don't miss a Thing! We will send you all news about Omega Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Omega Therapeutics Inc Stock News

Neutral
GlobeNewsWire
5 months ago
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will share new preclinical data at three upcoming scientific meetings.
Neutral
GlobeNewsWire
5 months ago
CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the publication of preclinical data from studies of OTX-2002 in Nature Communications. The article highlights the potential of Omega's approach to precis...

Company Profile

Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting, mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.

Head office United States
CEO Kaan Certel
Employees 94
Founded 2016
Website www.omegatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today